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ture between January 2006 and December 2011. Controls were matched with cases 
at a 4:1 ratio on the following characteristics: gender, age, geographic region, and 
date of first dispensing of a TZD or insulin prescription. We conducted conditional 
logistic regression analyses to estimate the odds ratios (ORs) of having a fracture 
associated with the use of insulin compared to TZD while controlling for other 
covariates. Results: There were 2,842 cases matched to 8,238 controls. The mean 
(standard deviation) age of the study subjects was 46.5 years (0.9) and 57.6% were 
women. Among cases, 32.8% used insulin and 67.2% used TZDs, and for controls 
30.3% used insulin and 69.7% used TZDs. The crude OR for insulin users compared 
with TZD was 1.14 (95% confidence interval [CI], 1.04-1.25). After adjustment for 
other antidiabetic drugs, comedication, and comorbidities, the OR was 1.28 (95% 
CI, 1.09-1.49). ConClusions: We found an association between use of insulin and 
fractures compared to TZDs in patients with COPD and DM. While further research 
is needed, clinicians and policy makers should assure that screening guidelines 
consider this relative risk in patients with COPD and DM.
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objeCtives: Prandial insulins are a key component in insulin treatment in type 1 
diabetes mellitus (T1DM) and many type 2 diabetes mellitus (T2DM) patients. The 
evidence supporting a choice between available insulin preparations is still limited. 
We performed a systematic review of clinical data comparing efficacy and safety 
of insulin aspart (IAsp) and regular human insulin (RHI) in both types of diabe-
tes. Methods: Randomized controlled trials (RCTs) directly comparing IAsp with 
RHI after ≥ 12 weeks of treatment in patients with either T1DM or T2DM receiving 
prandial insulin regimens were retrieved within systematic search of medical data-
bases (MEDLINE, EMBASE, Cochrane’s CENTRAL) carried out up to May 2013. Results 
from individual studies were meta-analyzed and presented as weighted mean dif-
ference (WMD) or relative risk (RR). Results: Of 16 RCTs considered relevant for 
the current review, 11 papers referred to T1DM and 5 were representative for T2DM 
patients. Pooled results for T1DM population demonstrated that IAsp as compared 
with RHI provided larger reduction of the HbA1c level (9 RCTs; WMD[95%CI]= -0.11% 
[-0.16, -0.05]) as well as better postprandial glucose level following breakfast (4 RCTs; 
WMD[95%CI]= -1.40mmol/L [-1.72, -1.07]), lunch (3 RCTs; WMD[95%CI]= -1.01mmol/L 
[-1.61, -0.41]) and dinner (4 RCTs; WMD[95%CI]= -0.89mmol/L [-1.19, -0.59]). The 
risk of nocturnal hypoglycemia was lower in T1DM patients treated with IAsp (4 
RCTs; RR= 0.76 [0.64, 0.91]), while no difference was observed for severe hypogly-
cemic events. In T2DM patients IAsp lead to a larger HbA1c reduction (5 RCTs; 
WMD[95%CI]= -0.22% [-0.39, -0.05]) and provided superior postprandial blood glucose 
control. The risk of hypoglycemia, either overall or severe events was comparable 
between arms. ConClusions: IAsp provided better glycemic control as compared 
with RHI in T1DM and T2DM in patients receiving prandial insulin regimen. T1DM 
patients treated with IAsp were less prone to develop nocturnal hypoglycemia, 
while both interventions presented comparable risk of severe hypoglycemic events.
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objeCtives: To support a German Federal Joint Committee (G-BA) submission, 
a systematic review and meta-analysis feasibility were conducted to assess the 
efficacy and safety of the GLP-1 receptor agonist exenatide against pre-defined 
comparators as required by the G-BA, for the management of patients with Type 2 
diabetes mellitus (T2DM). Both the short- (Byetta®) and long-acting (Bydureon®) 
exenatide formulations were eligible for inclusion. Methods: Database searches 
(accessed September 2013) were conducted to identify eligible randomised 
controlled trials (RCTs) that evaluated Byetta®/Bydureon® in one of the G-BA 
approved indications. In the absence of appropriate head-to-head studies, the fea-
sibility of conducting a robust meta-analysis was assessed for outcomes of inter-
est. Results: With regard to Byetta®, single head-to-head RCTs were identified for 
two G-BA required comparisons: Byetta®+metformin vs metformin+sulphonylurea 
(SU) and Byetta®+metformin+SU vs insulin+metformin. No head-to-head RCTs 
were identified that assessed Bydureon® vs G-BA comparators. However, two RCTs 
were identified which permitted an indirect comparison of Bydureon®+metformin 
vs metformin + SU via a common treatment (sitagliptin+metformin). Baseline 
patient characteristics (body weight 81–89 kg; HbA1C 7.5–8.6%; duration of diabetes 
5–7 years across treatment arms) and study duration (26-30 weeks) were compa-
rable between trials. Bucher indirect comparison results indicated that treatment 
with Bydureon®+metformin was associated with a significantly greater reduc-
tion in HbA1C (mean difference -0.53% [95% confidence interval (CI): -0.84, -0.22; 
p= 0.001]) and weight (mean difference -3.5kg [95% CI:-4.4, -2.6; p< 0.001]) and a 
significantly lower incidence of minor hypoglycaemia (odds ratio (OR) 0.03 [95% 
CI: < 0.00, 0.17; p< 0.001]) compared with metformin+SU. The incidence of adverse 
events (AEs) (OR 1.06 [95% CI: 0.63, 1.79 p= 0.821]) and serious AEs (OR 1.22 [95% 
CI: 0.26, 5.70; p= 0.800]) was similar. ConClusions: Indirect comparison results 
indicate that in patients with T2DM, treatment with Bydureon®+metformin is 
associated with significant efficacy benefits and a similar safety profile compared 
with metformin+SU.
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objeCtives: Basal insulin therapy is commonly initiated in type 2 diabetes (T2DM) 
patients with a long-acting insulin, such as insulin glargine or the intermediate-
acting insulin, NPH. In this study we evaluated the frequency of hypoglycemia 
associated with insulin glargine vs. NPH insulin treatment based on clinical trial 
results. Methods: A systematic search was conducted in PubMed to identify 
clinical trials (2000-2013) in which the efficacy and safety of insulin glargine and 
NPH insulin treatments were evaluated among patients with T2DM. The primary 
outcomes assessed in this review of clinical trial results were the frequencies of 
symptomatic and nocturnal hypoglycemia during trial periods. Of the 366 abstracts 
reviewed, 7 were of clinical trials with insulin glargine and NPH insulin treatment 
arms in which hypoglycemia frequency was reported. Results: A total of 1,389 
T2DM patients were treated with insulin glargine and 1,132 with NPH insulin. The 
frequency of symptomatic hypoglycemia was highly variable across the trials, rang-
ing from 35%-96% with insulin glargine and 41%-77% with NPH insulin, as was noc-
turnal hypoglycemia frequency, which ranged from 13%-31% with insulin glargine 
and 10%-40% with NPH insulin. Two of the 7 trials reported that the frequency of 
symptomatic hypoglycemia was significantly less among T2DM patients treated 
with insulin glargine vs. NPH insulin. Of the 5 trials reporting the frequency of 
nocturnal hypoglycemia 4 reported it was significantly less among T2DM patients 
treated with insulin glargine vs. NPH insulin. Differences in the change in HbA1c 
during trial periods were reported as non-significant in all studies, except for 2 
with morning insulin glargine arms. ConClusions: Based on clinical trial results 
insulin glargine and NPH insulin appear similar in glycemic efficacy, but treat-
ment with insulin glargine may be associated with less symptomatic and nocturnal 
hypoglycemia than treatment with NPH insulin. Additional studies are needed to 
confirm these findings.
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objeCtives: Health care providers managing older patients with type 2 diabetes 
mellitus (T2DM) face a complex milieu of medical conditions and comorbidities, 
which increase the risk of unintended treatment consequences. The objective of this 
study was to understand major factors associated with hypoglycemia-related hospi-
talizations among adults with T2DM with an emphasis on older patients. Methods: 
A large claims-based retrospective cohort study in the United States was undertaken 
on actively registered patients with a diagnosis of T2DM and at least one diabetes 
treatment prescription, which included an oral or insulin/injectable anti-diabetes 
therapy. The main outcomes assessed included hypoglycemia-related hospitaliza-
tion and readmission, frequency of comorbidities, and clinical outcomes. Results: 
Of patients with T2DM with hospitalization records (n= 887,182), 52.3% were male 
and 30.7% were aged ≥ 65 years. At baseline, the proportion of patients taking met-
formin was 52.4%, insulin 7.3%, and sulfonylurea 26.4%. Among those who experi-
enced a diabetes-related hospitalization, the incidence of hospitalization-related 
hypoglycemia in patients ≥ 65 years of age was greater than in patients < 65 years 
of age (0.59 compared to 0.16 per 1000 person years). Using boosted regression tree 
modeling, age (older vs. younger), sulfonylurea use, insulin use and renal disease 
were the variables most associated with predicting a hospitalization associated 
with hypoglycemia. Elderly patients prescribed both insulin and sulfonylurea were 
most likely to have hypoglycemia-related hospitalizations (odds ratio= 4.7; 95% CI 
3.7-6.1). ConClusions: Older patients using both insulin and sulfonylurea were 
the most likely to experience a hypoglycemia-related hospitalization in this study. 
Age, sulfonylurea use, insulin use, and renal disease were the top four influen-
tial variables to be associated with hypoglycemia-related hospitalization, while 
glucagon-like peptide and dipeptidyl peptidase-4 were less likely to be associated 
these events. More research is required to quantify the burden of these events 
given sulfonylurea and insulin are presently seen as a very effective and low cost 
treatment alternatives.
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objeCtives: Tight control of diabetes mellitus (DM) with insulin has the poten-
tial to increase hypoglycemic episodes which may result in fall and fracture risk. 
Moreover, patients with chronic obstructive pulmonary disease (COPD) are at high 
risk of fractures which may put patients with combination COPD and diabetes are 
particular risk. Our goal was to compare the risk of fractures associated with insulin 
use compared to TZDs in patients with COPD and DM. Methods: We conducted 
a nested case-control study using the IMS LifeLink® Health Plan Claims database, 
including patients at least 45 years old with a diagnosis of COPD and DM that were 
new users of either a TZD or insulin. Cases were individuals that experienced a frac-
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LDL-C control compared to those without CIC, suggesting that integrated systems 
may be beneficial to those with CIC.
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objeCtives: The first aim of this study is to collect individual-level patient data 
for a retrospective cohort study examining the demographics of patients diagnosed 
with Alpha Human Herpes Viruses (α -HHV) infection, and patients with low Thyroid 
levels (Thyroid disorder) over a 6-year period. The second aim is to test statistically 
that low Thyroid levels are related to higher prevalence of α -HHV. Methods: The 
data will be obtained from Peninsula Regional Medical Center located in Salisbury, 
Maryland. The adjusted medical claims will be identified using ICD-9-CM codes for 
the study period 2006-2012 of Thyroid disorders (240XX-246XX), HSV-1 (054XX) and 
VZV (053XX). The unique patients included in the sample will be identified with at 
least one medical claim for Thyroid disorder, and α -HHV diagnosis during the study 
period. Statistical analyses will be done using 2x2 contingency table developed 
by using patients with Thyroid disorder only, patients with α -HHV diagnosis only, 
patients that have both Thyroid disorder plus α -HHV diagnoses, and all patients 
without Thyroid or α -HHV diagnosis. The abstraction of the data will be done using 
Microsoft® Access and the statistical analysis will be done using SAS®9.3. Results: 
The preliminary analysis of the data revealed there were 4,551 patients with Thyroid 
disorder only, 217 patients with α -HHV diagnosis only, 85 patients that have both 
Thyroid disorder plus α -HHV diagnoses, and 1,46,963 patients without Thyroid or 
α -HHV diagnosis. The Odds ratio = 12.65 and p-value < 0.0001 (95% confidence 
Interval). ConClusions: The preliminary analysis reveals that odds of α -HHV reac-
tivations are approximately twelve times higher for the individuals with Thyroid 
disorders. And, Thyroid disorders are significantly associated with higher prevalence 
of α -HHV.
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objeCtives: Public and private US Payers use CQM to assess the quality of diabetes 
care and to incentivize improvement in care and associated outcomes. Examples 
of payers using CQMs include the Medicare Shared Savings Program (MSSP) and 
HealthPartners (HP). This post hoc analysis assessed CQM attainment with CANA 
and SITA in overweight/obese patients with T2DM. Methods: This analysis used 
pooled data from 2 previously published comparative randomized controlled clini-
cal trials that evaluated CANA and SITA treatment in patients with inadequate 
glycemic control on current therapy. CQM attainment was defined as achievement 
of combined glycated hemoglobin (HbA1c), blood pressure, and low density lipo-
protein cholesterol (LDL-C) thresholds. CQM attainment was assessed at baseline 
and 52 weeks, using last observation carried forward. Differences between CANA 
and SITA treatment groups were evaluated using 95% confidence intervals (CI) and 
odds ratios (OR) based on logistic regression. Results: Baseline characteristics of 
645 CANA and 649 SITA treated patients with body mass index > 25 kg/m42 and data 
for CQM assessment were similar. Baseline CQM attainment was similar between 
groups. At 52 weeks, CANA vs SITA demonstrated a greater likelihood of attaining 
CQMs. For the HP CQM HbA1c< 7%;BP< 130/80mmHg;LDL-C< 100mg/dL, CANA dem-
onstrated 4.9% (95% CI 1.2;8.5 and OR 1.94, 95% CI 1.30;2.91 ) better attainment. For 
the MSSP CQM HbA1c< 8%;BP< 140/90mmHg;LDL-C< 100mg/dL CANA demonstrated 
6.6% (95% CI 1.4;11.9 and OR 1.58, 95% CI 1.19;2.08) better attainment. Hypoglycemia 
rates for each group were similar. CANA was associated with higher rates of genital 
mycotic infections and adverse events related to osmotic diuresis, but with few 
study discontinuations. ConClusions: Compared to SITA 100 mg, CANA 300 mg 
treatment was associated with better CQM attainment in obese/overweight patients 
with T2DM. This information may inform payers on the comparative effectiveness of 
antihyperglycemic agents on attainment of diabetes CQMs which include glycemic, 
blood pressure, and lipid endpoints.
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objeCtives: The objective was to examine the evidence on the efficacy of current 
treatments in patients with Cushing’s disease (CD) to support health care decision-
making. Methods: A systematic literature search using predefined strategy was 
performed in the Cochrane library, EMBASE, PUBMED and MEDLINE to identify 
observational studies in North America and Europe from 2003 to 2013. A total of 
32 studies were included and analyzed, out of 791 studies found. Results: For 
primary CD (n= 23/32), transsphenoidal surgery (TSS) remains the procedure of 
choice (n= 20/23, 87% of studies). For recurrent/persistent disease (n= 11/32), treat-
ment received was; TSS in 36.3%, radiotherapy in 27.35%, bilateral adrenalectomy 
(BLA) in 18.2% and medical therapy in 18.2%. Remission rates post primary TSS 
were 65%-91% with recurrence of 5%-24%. Variability in remission rate could be 
attributed to the lack of uniformity in the definition for remission, different length 
of follow-up, patient population (macro- vs. micro-adenomas), surgeon experience 
and the type of TSS technique used (endoscopic vs. microscopic). Remission rate was 
lower for recurrent/persistent CD (37.5%-71%).Major complications were; diabetes 
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Deng Y, Guo J.J., Lin A.C.
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objeCtives: The discussion around the cardiovascular risk caused by rosiglitazone 
continues, as the results from recent pharmacoepidemiologic studies were believed 
inconclusive. The objective of this study is to do a descriptive study on the adverse 
events, especially cardiovascular events caused by rosiglitazone and other com-
monly used anti-diabetes agents. Methods: FDA adverse event reporting system 
(FAERS) database was used for data analysis; reports were drawn from 1997 to 2011. 
Study drugs include rosiglitazone, pioglitazone, metformin, glipizide and glyburide. 
Adverse events during time were calculated to see the trend. Frequency of different 
adverse events described and stratified by age and gender. Different outcomes like 
the cardiovascular events, death and hospitalization associated with each study 
drug were calculated each year. Results: The adverse events of all drugs did not 
vary much during years, except that rosiglitazone has a sharply increase from 
2008 and decreased in 2011, in accordance with the 2007 meta-analysis published. 
Adverse events of different drugs differ in gender: there are 10% more adverse 
events of glyburide and 14% more of rosiglitazone in male than female; while met-
formin cause 8% more in female than male. Rosiglitazone has significantly more 
deaths (5568) and hospitalizations (28387) comparing to other four drugs (average 
2225 death and 11521 hospitalization), and it also has more cardiovascular events 
(36.37%) than other four drugs (average 11.52%). ConClusions: Rosiglitazone 
seems to have more and severe adverse events, especially cardiovascular events 
comparing to other four antidiabetic drugs.
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objeCtives: Intramuscular (IM) testosterone injections have been available since 
1953 but significant immediate adverse reactions have not been well documented. 
The objective was to estimate the rate of anaphylaxis associated with IM testoster-
one injections. Methods: This retrospective analysis utilized a large commercial 
claims database. Study sample consisted of males who received office-based IM 
testosterone injection(s) between 2007 and 2011. Anaphylaxis cases were selected 
from medical claims based on the ICD-9-CM 995.0 (other anaphylactic reaction), 
occurring on the same day of the testosterone injection. The relationship between 
testosterone injections and anaphylaxis were classified as “likely, probably, pos-
sible, unlikely” based on the clinical review of patient’s medical history, treatment 
for anaphylaxis and existence of confounding diagnoses. The outcomes were the 
number of patients with anaphylaxis per 10,000 patients and the number of anaphy-
laxis cases per 10,000 person-years. Results: Between 2007 and 2011, 989,778 IM 
testosterone injections were identified for a total of 120,402 males (mean age: 49.1 
years). A total of 232 patients had at least one anaphylaxis claim within 365 days of 
receiving an IM testosterone injection. Among 40 same-day anaphylaxis cases (39 
patients), there were 12 cases (12 patients) with anaphylaxis classified as “likely” 
or “probable”, which represent a rate of 1.0 patient per 10,000 patients, or 1.5 cases 
per 10,000 person-years. There were 17 cases (16 patients) with anaphylaxis classi-
fied as “likely”, “probable”, or “possible”. In comparison, there were only 19 cases of 
anaphylaxis identified from the FDA Adverse Event Reporting System (FAERS) from 
1/1969 to 1/2013 (44 years). ConClusions: Our study showed that, although rare, 
anaphylaxis-related events have been documented to occur following IM testos-
terone injections. Given the limitations of spontaneous reporting of adverse events 
for marketed products, claims databases can be utilized to complement FAERS in 
identifying safety signals for drugs, especially older drugs.
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objeCtives: To assess clinical outcomes among individuals having chronic illness 
with complexity (CIC) defined as co-occurring type 2 diabetes mellitus (T2DM) 
and Parkinson’s disease (PD). Methods: This study used a retrospective cohort 
design using Humana Medicare Advantage Part D claims database (2007-2011) and 
included elderly (age ≥ 65 years) Medicare beneficiaries with T2DM (identified by 
ICD-9-CM code of 250.x0 or 250.x2). PD was identified using ICD-9-CM code of 332.
xx. Individuals with T2DM and PD (CIC) were matched to those with T2DM and no 
PD (no CIC) on sex, age, and diabetes complications severity index based on 8 to 1 
GREEDY matching algorithm using propensity score. After propensity score match-
ing there were 2,703 individuals with T2DM and PD and 8,109 with T2DM and no PD. 
Glycemic control outcomes [(i) < 8%, (ii) ≥ 8%, (iii) no HbA1c values] and lipid control 
outcomes [based on Low Density Lipoprotein Cholesterol (LDL-C) categorized into 
(i) < 100 mg/dl, (ii) ≥ 100mg/dl, (iii) no LDL-C values] were measured during the year 
subsequent to the identification of T2DM and PD. Multinomial conditional logistic 
regressions were conducted to examine the association between PD and clinical 
outcomes. Results: Among those with laboratory values, 86.1% individuals with 
PD and 83.8% individuals without PD had < 8% HbA1c value; the corresponding fig-
ures for LDL-C value of < 100mg/dl were 75.5% and 69.8% respectively. Multinomial 
conditional logistic regressions revealed that individuals with PD were more likely 
than those without PD to have good glycemic control of < 8% HbA1c (reference group: 
≥ 8% HbA1c) (AOR: 1.34, 95%CI: 1.10-1.63) and good LDL-C control of < 100mg/dl 
(reference group: ≥ 100mg/dl LDL-C) (AOR: 1.29, 95%CI: 1.03-1.63). ConClusions: 
Individuals with CIC were more likely to have clinically recommended glycemic and 
